Alnylam: Q2 Earnings Snapshot

Associated Press Finance
1-min read
In this article:

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $16.9 million in its second quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 13 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 56 cents per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 74 cents per share.

The RNA interference drug developer posted revenue of $659.8 million in the period, which also topped Street forecasts. Eleven analysts surveyed by Zacks expected $448.4 million.

Alnylam shares have climbed 24% since the beginning of the year. The stock has increased 22% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY